U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details


; .

Author Information and Affiliations

Last Update: July 10, 2023.

Continuing Education Activity

Dyslipidemia is the imbalance of lipids such as cholesterol, low-density lipoprotein cholesterol, (LDL-C), triglycerides, and high-density lipoprotein (HDL). This condition can result from diet, tobacco exposure, or genetic and can lead to cardiovascular disease with severe complications. This activity describes the evaluation and management of dyslipidemia and highlights the role of the interprofessional team in improving care for patients with this condition.


  • Identify the etiology and epidemiology of dyslipidemia medical conditions and emergencies.
  • Review the evaluation of dyslipidemia.
  • Outline the management options available for dyslipidemia.
  • Discuss interprofessional team strategies for improving care coordination and communication to advance dyslipidemia and improve outcomes.
Access free multiple choice questions on this topic.


Lipids, such as cholesterol or triglycerides, are absorbed from the intestines and are carried throughout the body via lipoproteins for energy, steroid production, or bile acid formation. Major contributors to these pathways are cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and high-density lipoprotein (HDL). An imbalance of any of these factors, either from organic or nonorganic causes, can lead to dyslipidemia.[1]


Several health behaviors can have effects and increase lipid levels. Examples include tobacco use, physical inactivity, nutrition, and obesity. Specifically, nutrition risk factors include the insufficient consumption of fruits, nuts/seeds, vegetables, or high consumption of saturated fats. 

Dyslipidemia can be due to familial disorders as well. Autosomal dominant mutations cause most cases of familial hypercholesterolemia in LDL receptors, which causes an elevation in LDL-C levels. Other mutations in the cholesterol pathway have been identified but are less common.[2][3]


The prevalence of dyslipidemia increases with age. In 2005-2008 an estimated 33.5% of U.S. adults older than 20 years of age had high LDL-C levels. Of these individuals with elevated LDL-C levels, only 48.1% received treatment, and 33.2% had their LDL-C controlled. The prevalence of LDL-C control seemed to be the lowest amongst individuals that were uninsured, Mexican American, or having income below the poverty level.[4]

History and Physical

History is essential in identifying high-risk individuals. Most importantly, social history would include tobacco use or specific details about diet. Past medical history is vital in identifying patients who will need primary prevention versus secondary prevention if statin therapy requires initiation. Lastly, family history is important to identify familial hypercholesterolemia. 

The physical exam is limited in dyslipidemia disorders. Xanthomas are deposits of lipids on the skin and sometimes subcutaneous tissue. They are yellowish and can form into plaques, nodules, or plaques. They can present on the palmar crease, which suggests familial dysbetalipoproteinemia, eyelids, or tendons. They typically are associated with hyperlipidemia, and if seen, the patient should have screening for dyslipidemia.[5]


The primary evaluation tool for dyslipidemia is a fasting lipid panel which consists of total cholesterol, LDL, HDL, and triglycerides. There is some debate on at what age dyslipidemia screening should start. The United States Preventative Services Task Force recommends screening all males 35 and older as well as high-risk males age 20 to 35. Also, all-woman 45 years and older as well as high-risk individuals 20 to 45 years of age. Other recommendations suggest getting fasting lipid panels for all individuals age 20 to 78 years at least every five years if no atherosclerotic disease is present.[6]

Classification of dyslipidemia subdivides into five different categories, according to Frederickson phenotype. Phenotype I is an abnormality of chylomicrons and will result in triglycerides greater than 99 percentiles. Phenotype IIa consists mainly of LDL cholesterol abnormality and will have total cholesterol concentration greater than 90 percentile and possible apolipoprotein B greater than 90 percentile. Phenotype IIb consists of abnormality in LDL and very-low-density lipoprotein (VLDL) cholesterol. This type will result in total cholesterol and/or triglycerides greater than 90 percentile and apolipoprotein greater than 90 percentile. Phenotype III is an abnormality in VLDL remnants and chylomicrons, which results in elevated total cholesterol and triglycerides greater than 90 percentile. Phenotype IV is mainly when VLDL is abnormal and will result in total cholesterol greater than 90 percentile. This type can also present with triglycerides greater than 90 percentile and low HDL. Phenotype V is when chylomicrons and VLDL are abnormal, and triglycerides are greater than 99 percentiles.[7]

Treatment / Management

Initial management for dyslipidemia involves lifestyle modifications. This approach should include a diet with an emphasis on the intake of vegetables, fruits, and whole grains within an appropriate calorie requirement. Also, adults should participate in moderate to vigorous aerobic physical activity 3 to 4 times a week for at least 40 minutes. First-line treatment for dyslipidemia is statins that inhibit 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) reductase.

Patients with clinically significant atherosclerotic cardiovascular disease (ASCVD) (acute coronary syndromes, history of myocardial infarction, stable or unstable angina, arterial revascularization, and stroke) and are less than 75 years of age should be put on a high-intensity statin. Patients that are greater than 75 years of age with clinical ASCVD should be on a moderate-intensity statin. High-intensity statin therapy should start if the patient is 40 and 75 years old and has LDL-C greater than or equal to 190 mg/dL or has a history of diabetes and LDL-C between 70 to 189 mg/dL. Patients should be on a moderate or high-intensity statin if age 40 to 75 years old, LDL-C between 70 to 189 mg/dL, and have 10-year ASCVD greater than or equal to 7.5%. The clinician-patient discussion should be undertaken to discuss the introduction of high or moderate-intensity statin in situations such as less than 5% to 7.5% 10-year ASCVD risk. 

For primary prevention, statin therapy should lower LDL-C approximately 30% to less than 50% with a moderate-intensity statin and greater than or equal to 50% with a high-intensity statin. High-intensity statins are atorvastatin 40 or 80 mg and rosuvastatin 20 mg. Some moderate-intensity statins atorvastatin 1 0mg, rosuvastatin 10 mg, simvastatin 20 mg or 40 mg, pravastatin 10 mg, etc.

For secondary prevention, as defined by a patient who has coronary artery disease, a target goal is set for LDL-C less than 70 mg/dL after being placed on a high-intensity statin for six weeks. If this goal is not met and LDL-C is significantly greater than 70, then combination therapy should be started in addition to high-intensity statin. If the patient is not high-risk, then the LDL-C goal should remain less than 70 mg/dL. If the patient is a high risk (already had acute coronary syndrome in the last year, familial hypercholesterolemia, diabetes, chronic kidney disease (stage 3 or 4), or atherosclerotic cardiovascular disease event, or the need for revascularization while on a statin), then the LDL goal should be less than 50 and if not met another agent should be added. 

Currently, there are two classes of medications that are recommended with statin therapy because they have shown to decrease cardiovascular outcomes. One of these is ezetimibe, which inhibits the absorption of cholesterol. This drug can lower LDL-C an additional 25% in combination with statin therapy.

Another category targets proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates the LDL receptor. An increase in PSCK9 decreases LDL receptors and therefore increases LDL levels in the blood. PCSK9 inhibitors are monoclonal antibodies that bind PCSK9 and, in doing so, decrease LDL-C levels.

The new agent inclisiran is an interfering ribonucleic acid drug that stops the production of PCSK9 with twice a yearly dosing. This agent may be beneficial in patients who are intolerant of LDL lowering medications. As of this writing, it has not yet received FDA approval in the USA.

Icosapent ethyl is an FDA approved medication that has been shown to reduce cardiovascular risk in patients with elevated triglycerides in addition to maximal statin therapy.

Bempedoic acid is another drug that is an option for people intolerant to statins in combination with ezetimibe. This drug works by inhibiting adenosine triphosphate citrate lyase, which helps make cholesterol in the liver and therefore decreasing levels. Many other new and exciting medications are in current research to help lower cholesterol levels and prevent cardiovascular events.

Other categories of treatment that have not been shown to reduce cardiovascular events but have been useful in dyslipidemia therapy are bile acid sequestrants such as cholestyramine, colestipol, and colesevelam, which decrease bile acid reabsorption, therefore, increasing clearance of LDL-C and decreasing levels. Fibric acid derivatives (fibrates) are peroxisome proliferator-activated receptor agonists. These have shown to increase HDL-C and reduce triglycerides. However, in combination with statins can increase the risk of myopathy and rhabdomyolysis, which can cause generalized muscle pain. Current guidelines recommend against the use of statins and gemfibrozil. Niacin has shown to increase HDL and reduce VLDL, which also decreases LDL but has a significant side effect profile with the greatest being flushing. Taking aspirin can decrease the occurrence of this side effect.[8][9][10][11][12][13]

Differential Diagnosis

  • Nephrotic syndrome
  • Biliary obstruction
  • Hypothyroidism
  • Pregnancy
  • Drugs (oral estrogens, glucocorticoids, tamoxifen, thiazides)[9]


One tool that clinicians can use to calculate the prognosis of a patient with dyslipidemia is 10-year atherosclerotic cardiovascular disease risk. This calculator factors in risk for patients based on lipid levels as well as age, race, tobacco use, diabetes, sex, and hypertension history. This calculation will give a percentage of risk that a cardiovascular event will happen in 10 years. Also, a percentage of risk if risk factors were optimal.[14]


The most significant complication for dyslipidemia is cardiovascular disease. Complications of this include sudden cardiac death, acute myocardial infarction, or stroke. Multiple studies have demonstrated that statin and appropriate dyslipidemia treatment has significantly reduced the risk of all-cause mortality, cardiovascular events, and cardiovascular mortality.[15]

Deterrence and Patient Education

As discussed above, patients need to recognize and adhere to specific health behaviors that can maintain and lower lipid levels. These include, but are not limited to, weight control, which includes a heart-healthy diet and exercise as well as avoidance of tobacco. Patients should also engage in conversation with their primary care providers on when to start getting screened or when to initiate treatment, as stated above.

Enhancing Healthcare Team Outcomes

Enhancing healthcare outcomes for patients with dyslipidemia has to involve a multidisciplinary treatment team, including clinical physicians such as cardiologists or endocrinologists, nurses, and pharmacists. Clinicians have to be aware of up to date guidelines on lipid screening, indication for treatment, and goals LDL-C levels. Nurses should adhere to the same awareness as physicians but also aid in maintaining close follow up with these patients to help improve adherence to medications. Pharmacists can assist in watching for drug interactions, counseling regarding potential adverse effects, and providing dosing instruction.

Review Questions


Rader DJ, Hoeg JM, Brewer HB. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994 Jun 15;120(12):1012-25. [PubMed: 8185133]
Writing Group Members. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB., American Heart Association Statistics Committee. Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-360. [PubMed: 26673558]
Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017 Dec 07;3:17093. [PubMed: 29219151]
Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200. MMWR Morb Mortal Wkly Rep. 2011 Feb 04;60(4):109-14. [PubMed: 21293326]
Lugo-Somolinos A, Sánchez JE. Xanthomas: a marker for hyperlipidemias. Bol Asoc Med P R. 2003 Jul-Aug;95(4):12-6. [PubMed: 15032023]
Kopin L, Lowenstein C. Dyslipidemia. Ann Intern Med. 2017 Dec 05;167(11):ITC81-ITC96. [PubMed: 29204622]
Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med. 1971 Sep;75(3):471-2. [PubMed: 5568160]
Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC, Svetkey LP, Wadden TA, Yanovski SZ., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 01;63(25 Pt B):2960-84. [PubMed: 24239922]
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PW., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 01;63(25 Pt B):2889-934. [PubMed: 24239923]
Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs Context. 2018;7:212534. [PMC free article: PMC6044319] [PubMed: 30023003]
Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017 Jun;23(9 Suppl):S139-S148. [PubMed: 28978219]
Mills EJ, O'Regan C, Eyawo O, Wu P, Mills F, Berwanger O, Briel M. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J. 2011 Jun;32(11):1409-15. [PubMed: 21385791]
Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM., CLEAR Harmony Trial. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019 Mar 14;380(11):1022-1032. [PubMed: 30865796]
Muntner P, Colantonio LD, Cushman M, Goff DC, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014 Apr 09;311(14):1406-15. [PMC free article: PMC4189930] [PubMed: 24682252]
Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016 Nov 15;316(19):2008-2024. [PubMed: 27838722]

Disclosure: Nikos Pappan declares no relevant financial relationships with ineligible companies.

Disclosure: Anis Rehman declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK560891PMID: 32809726


  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...